Business models and provider satisfaction in in-vitro fertilization centers in the United States

Jessica McLaughlin(The University of Texas at San Antonio Health Science Center), Randal D. Robinson(The University of Texas at San Antonio Health Science Center), Jennifer F. Knudtson(The University of Texas at San Antonio Health Science Center), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center), Norma S. Ketchum(The University of Texas at San Antonio Health Science Center), Robert S. Schenken(The University of Texas at San Antonio Health Science Center)
Fertility and Sterility
March 1, 2018
10.1016/j.fertnstert.2018.02.073
Cited by 3

Related Papers

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial
|JAMA|1995|605
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women
|JAMA|2010|565
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
|New England Journal of Medicine|2009|468
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial
|The Lancet Oncology|2012|360
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
|EBioMedicine|2023|275